{
    "root": "3088f764-b69d-e219-e063-6294a90a336a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lacosamide",
    "value": "20250317",
    "ingredients": [
        {
            "name": "ACESULFAME POTASSIUM",
            "code": "23OV73Q5G9"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM",
            "code": "K679OBS311"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "METHYLPARABEN SODIUM",
            "code": "CR6K9C2NHK"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "LACOSAMIDE",
            "code": "563KS2PQY5"
        }
    ],
    "indications": "lacosamide oral solution indicated : • treatment partial-onset seizures patients 1 month age older ( 1.1 ) • adjunctive therapy treatment primary generalized tonic-clonic seizures patients 4 years age older ( 1.2 )",
    "contraindications": "adults ( 17 years older ) : initial monotherapy treatment partial-onset seizures 100 mg twice daily ( 2.1 ) initial adjunctive therapy treatment partial-onset seizures primary generalized tonic-clonic seizures 50 mg twice daily ( 2.1 ) maximum recommended monotherapy adjunctive therapy 200 mg twice daily ( 2.1 ) pediatric patients 1 month less 17 years : recommended based body weight administered orally twice daily ( 2.1 ) increase based response tolerability , frequently per week ( 2.1 ) dose adjustment recommended severe renal impairment ( 2.4 , 12.3 ) dose adjustment recommended mild moderate hepatic impairment ; patients severe hepatic impairment recommended ( 2.5 , 12.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "Lacosamide oral solution is indicated for: • Treatment of partial-onset seizures in patients 1 month of age and older ( 1.1 ) • Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older ( 1.2 )",
    "contraindications_original": "Adults (17 years and older): o Initial dosage for monotherapy for the treatment of partial-onset seizures is 100 mg twice daily ( 2.1 ) o Initial dosage for adjunctive therapy for the treatment of partial-onset seizures or primary generalized tonic-clonic seizures is 50 mg twice daily ( 2.1 ) o Maximum recommended dosage for monotherapy and adjunctive therapy is 200 mg twice daily ( 2.1 ) Pediatric Patients 1 month to less than 17 years: The recommended dosage is based on body weight and is administered orally twice daily (2.1) Increase dosage based on clinical response and tolerability, no more frequently than once per week (2.1) Dose adjustment is recommended for severe renal impairment ( 2.4, 12.3 ) Dose adjustment is recommended for mild or moderate hepatic impairment; use in patients with severe hepatic impairment is not recommended ( 2.5 , 12.3)",
    "adverseReactions_original": "None."
}